MLTX NASDAQ
MoonLake Immunotherapeutics
1W: -17.6%
1M: -27.4%
3M: -29.5%
YTD: +4.7%
1Y: -76.9%
3Y: -75.0%
5Y: +26.6%
$12.51
-0.67 (-5.08%)
Weekly Expected Move ±5.8%
$11
$12
$13
$13
$14
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.1B
52W Range5.95-62.75
Volume2,382,794
Avg Volume1,180,376
Beta1.04
Dividend—
Analyst Ratings
Company Info
CEOJorge Santos da Silva
Employees130
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-20
Websitemoonlaketx.com
Dorfstrasse 29
Zug, ZG 6300
CH
Zug, ZG 6300
CH
41 415108022
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Latest News
HC Wainwright Issues Negative Estimate for MLTX Earnings
MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial - Fierce Biotech
Why is MoonLake Immunotherapeutics stock plunging today?
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Reich Kristian | S-Sale | 1,100 | $20.00 | 2026-07-27 |
| Reich Kristian | S-Sale | 2,448 | $20.00 | 2026-07-22 |
| Reich Kristian | S-Sale | 50,000 | $20.02 | 2026-07-21 |
| Reich Kristian | S-Sale | 43,700 | $20.09 | 2026-07-20 |
| Reich Kristian | S-Sale | 16,105 | $20.01 | 2026-07-15 |